<DOC>
	<DOCNO>NCT00221754</DOCNO>
	<brief_summary>To assess use pravastatin hypercholesterolemic HIV-infected patient treat protease inhibitor randomise double blind study .</brief_summary>
	<brief_title>Pravastatin Protease Inhibitors HIV-Infected Patients</brief_title>
	<detailed_description>Background . Highly Active AntiRetroviral Therapy include protease inhibitor associate elevated plasma lipid level . Design . randomize double-blind , multicentric . Intervention . Pravastatin versus placebo 12 week . Eligibility criterion . Positive anti-VIH antibody , stable antiretroviral therapy include least one PI &gt; = 3 month , plasma HIV-RNA level &lt; 50 copies/mL &gt; = 3 month randomization , total cholesterol &gt; = 5.5 mmol/L LDL-cholesterol &gt; = 3.4 mmol/L fasting status three month standardize dietary advice , write informed consent Outcomes . HIV RNA 12 week</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>confirm HIV1 infection ( ELISA confirm WesternBlot test ) ; Age 18 year Stable antiretroviral therapy include least one PI &gt; = 3 month , Plasma HIVRNA level &lt; 50 copies/mL &gt; = 3 month randomization , Total cholesterol &gt; = 5.5 mmol/L LDLcholesterol &gt; = 3.4 mmol/L fasting status three month standardize dietary advice , sign inform consent Current AIDS event infectious disease Tumoral , inflammatory , muscle disease ; kidney hepatic failure Psychiatric condition Biological elevate muscular enzyme Chronic alcohol consumption Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>HIV ,</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>pravastatin</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>